Technical Service Need help? Our team of experienced experts is here for you with full support.
AKA-382
Cobimetinib Fumarate
Cat. No.
AKA-382
CAS No.
1369665-02-0
MF
C46H46F6I2N6O8
MW
1178.69
Cobimetinib Hemifumarate is a potent and selective MEK1/2 inhibitor that suppresses MEK kinase activity and modulates the RAF–MEK–ERK signaling pathway, demonstrating significant potential in targeted anticancer drug research and development.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service 
86-28-85159085 
info@aktin.com
Technical Data
Description
Storage and Shipping
References
Product Name
Cobimetinib Fumarate
CAS No.
1369665-02-0
MF
C46H46F6I2N6O8
MW
1178.69
Specification
98%
Target
MEK1/MEK2
Documents
Certificate of Analysis (COA), API specification, Safety Data Sheet (SDS/MSDS), evidence of GMP compliance, Stability data / Stability summary, etc.
Description
Cobimetinib Hemifumarate is a potent and selective MEK1/2 inhibitor that suppresses MEK kinase activity and modulates the RAF–MEK–ERK signaling pathway, demonstrating significant potential in targeted anticancer drug research and development. Chemical name：(E)-but-2-enedioic acid;bis([3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone) Packing：1kg/Bag，5kg/Bag，10kg/Bag Availability: In stock API Current Development Status: A3---Process Development / Scale-Up Reference: Aktin major API development processes: A1.Feasibility / Route Development A2.Laboratory Process Development A3.Process Development / Scale-Up A4.GMP Clinical Development A5.Commercial GMP Supply
Storage and Shipping
Store in a cool and dry place, avoid strong light and high temperature.
References
[1].Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini JF, et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res. 2012;18(11):3090-9. doi: 10.1158/1078-0432.CCR-12-0445
[2].Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-76. doi: 10.1056/NEJMoa1408868
[3].Rice KD, Aay N, Anand NK, Blazey CM, Bowles OJ, Bussenius J, et al. Novel carboxamide-based allosteric MEK inhibitors: discovery and optimization efforts toward XL518 (GDC-0973). ACS Med Chem Lett. 2012;3(5):416-421. doi: 10.1021/ml300049d
Disclaimer
The information provided on generic APIs is for general reference and market assessment purposes only. Regulatory status, market availability, specifications, patents, and commercial terms may vary by country and change over time. Users should independently verify all information with the relevant regulatory authorities and qualified professionals before making any regulatory, manufacturing, investment, or commercial decisions. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
AKA-384
Tedizolid phosphate
CAS No.: 856867-55-5
MF:C17H16FN6O6P
AKA-383
Brivaracetam
CAS No.:357336-20-0
MF:C11H20N2O2
AKA-379
Bempedoic acid
CAS No.:738606-46-7
MF:C19H36O5
AKA-378
Borofalan(10B)
CAS No.:80994-59-8
MF:C9H12BNO4
AKA-377
AkProva™ Metildigoxin
CAS No.:30685-43-9(acetone-free)
MF:C42H66O14.1/2C3H6O
AKA-376
AkProva™ beta-Acetyldigoxin
CAS No.:5355-48-6
MF:C43H66O15
AKA-375
Ak-NucleoVia™ Agrostemmoside E
CAS No.:2656438-29-6
MF:C84H128O45
AKA-374
Novobiocin sodium
CAS No.:1476-53-5
MF:C31H35N2NAO11
AKA-360
Travoprost
CAS No.:157283-68-6
MF:C26H35F3O6
AKA-359
Berberine sulfate
CAS No.:316-41-6
MF:C20H18NO4.1/2O4S
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
